Tixagevimab/AZD8895 represents a novel therapeutic method utilizing two monoclonal immunoglobulins. Specifically, these agents function by specifically connecting to the receptor-binding domain of the SARS-CoV-2 agent, hindering its ability to fuse with host cells. This blockade of viral penetration primarily neutralizes the infection before it can